Tue, Jul 22, 2014, 9:24 AM EDT - U.S. Markets open in 6 mins.

Recent

% | $
Click the to save as a favorite.

Inovio Pharmaceuticals, Inc. Message Board

jbarba_us 2 posts  |  Last Activity: May 12, 2014 8:13 AM Member since: Aug 28, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Inovio Pharmaceuticals Reports 2014 First Quarter Financial Results

    BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2014.

    Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period in 2013. Total operating expenses were $12.4 million compared to $8.1 million.

    The loss from operations prior to other income (expenses) for the quarter ended March 31, 2014, was $10.0 million, or $0.05 per share, as compared with $6.6 million, or $0.04 per share for the quarter ended March 31, 2013.

    The net loss attributable to common stockholders for the quarter ended March 31, 2014, was $10.8 million, or $0.05 per share as compared with a net loss attributable to common stockholders of $8.8 million, or $0.06 per share for the quarter ended March 31, 2013.

    The $2.0 million increase in net loss attributable to common stockholders for the quarter ended March 31, 2014, compared with the same period in 2013 resulted primarily from an increase in non-cash stock-based compensation.

    Revenue

    The increase in revenue for the three-month period was primarily due to $1.4 million of revenue recognized from our agreement with Roche. This revenue from Roche primarily consisted of development fees paid for work conducted by Inovio in Q1.

    Operating Expenses

    Research and development expenses for Q1 2014 were $8.2 million compared to $5.1 million for Q1 2013. General and administrative expenses were $4.1 million versus $3.0 million, respectively.

    Capital Resources

    As of March 31, 2014, cash and cash equivalents plus short-term investments were $116.8 million compared with $52.6 million as of December 31, 2013.

    On March 4, 2014, the Company closed an underwritten public offering of 21,810,900 shares of the Company's common stock, including 2,844,900 shares of common stock issued pursuant to the underwriter's exercise of its over

    Sentiment: Buy

  • jbarba_us jbarba_us Apr 22, 2014 10:29 PM Flag

    Thanks Mensa. I bit the apple right after I read the post. 10k at $.61/share. I also have 25k of INO and 53k of ONCS. Keep us posted on any programs notes/updates on your PBS appearance this May.

    Sentiment: Buy

INO
11.01Jul 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.